Stay updated on Pembrolizumab in EOC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in EOC Clinical Trial page.

Latest updates to the Pembrolizumab in EOC Clinical Trial page
- Check2 days agoChange DetectedRevision label updated to v3.4.3 (previously v3.4.2). This appears to be a minor site version change and does not modify study data or content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedFallopian tube cancer added as a condition and the page updated to version 3.4.2; the government funding status notice has been removed.SummaryDifference0.5%

- Check37 days agoChange DetectedA site-wide government funding/status notice was added and the page version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check44 days agoChange DetectedAdded a Show glossary control and updated metadata labels, including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision to v3.4.0 (from v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check59 days agoChange DetectedRevision: v3.3.4 updates the page revision label (replacing v3.3.3). This change does not affect any study data or content presented on the page.SummaryDifference0.1%

- Check80 days agoChange DetectedAdded a Locations section with Florida as a location and removed the separate Florida Locations entry; the HHS Vulnerability Disclosure link was removed. Revision tag updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab in EOC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in EOC Clinical Trial page.